ASH 2023 | GvHD prophylaxis post-alloSCT: PTCy versus ATG
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses a study comparing graft-versus-host disease (GvHD) prophylaxis with anti-thymocyte globulin (ATG)-based combination therapy versus post-transplant cyclophosphamide (PTCy)-based combination therapy post allogeneic stem cell transplantation (alloSCT) in acute myeloid leukemia (AML). The study found no difference in overall survival (OS) or leukemia-free survival (LFS), but non-relapse mortality (NRM) was reduced in the PTCy arm. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
